The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus
Abstract
Tenofovir is an acyclic nucleotide analog with activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Tenofovir disoproxil fumarate (tenofovir DF), a bis-alkoxyester prodrug of tenofovir, is approved for the treatment of HIV and is currently being developed to treat chronic hepatitis B. In this report, we further characterize the in vitro activity of tenofovir against HBV as well as its metabolism in hepatic cells. We show that tenofovir is efficiently phosphorylated to tenofovir diphosphate (TFV-DP) in both HepG2 cells and primary human hepatocytes. TFV-DP has a long intracellular half-life (95 h) and is a potent and competitive inhibitor of HBV polymerase (K i= 0.18 μM). Tenofovir has a 50% effective concentration of 1.1 μM against HBV in cell-based assays, and potency is improved >50-fold by the addition of bis-isoproxil progroups. Tenofovir has previously demonstrated full activity against lamivudine-resistant HBV in vitro and clinically. Here we show that the major adefovir resistance mutation, rtN236T, confers three- to fourfold-reduced susceptibility to tenofovir in cell culture; the clinical significance of this susceptibility shift has not yet been determined. The rtA194T HBV polymerase mutation recently identified in tenofovir DF-treated HIV/HBV-coinfected patients did not confer in vitro resistance to tenofovir as a single mutation or in a lamivudine-resistant viral background. Overall, the antiviral and metabolic profile of tenofovir supports its development for the treatment of chronic hepatitis B.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maniatis, T. (1989) · Medical Entomology and Zoology · Cited by 1,171
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,033
Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel
Yeni, P. G., Hammer, S. M., Hirsch, M. S., Saag, M. S., Schechter, M., Carpenter, C. C. J., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Jacobsen, D. M., et al. (2004) · JAMA · doi:10.1001/jama.292.2.251 · Cited by 737
Acyclic nucleoside phosphonates: a key class of antiviral drugs
Clercq, E. D., & Holý, A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1877 · Cited by 688
Lai, C., Dienstag, J., Schiff, E., Leung, N. W. Y., Atkins, M., Hunt, C., Brown, N., Woessner, M., Boehme, R., & Condreay, L. (2003) · Clinical Infectious Diseases · doi:10.1086/368083 · Cited by 634
Angus, P., Vaughan, R., Xiong, S., Yang, H., Delaney, W., Gibbs, C., Brosgart, C., Colledge, D., Edwards, R., Ayres, A., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00939-9 · Cited by 564
Self-citationPeters, M. G., Hann, H. W., Martin, P., Heathcote, E. J., Buggisch, P., Rubin, R., Bourliere, M., Kowdley, K., Trepo, C., Gray, D. F., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.051 · Cited by 552
Self-citationGünther, S., Li, B. C., Miska, S., Krüger, D. H., Meisel, H., & Will, H. (1995) · Journal of Virology · doi:10.1128/jvi.69.9.5437-5444.1995 · Cited by 499
Tenofovir Disoproxil Fumarate: Clinical Pharmacology and Pharmacokinetics
Kearney, B. P., Flaherty, J. F., & Shah, J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443090-00003 · Cited by 456
van Bömmel, F., Wünsche, T., Mauss, S., Reinke, P., Bergk, A., Schürmann, D., Wiedenmann, B., & Berg, T. (2004) · Hepatology · doi:10.1002/hep.20464 · Cited by 389
Cited by
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
Zoulim, F., & Locarnini, S. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.063 · Cited by 706
Buti, M., Gane, E., Seto, W. K., Chan, H. L. Y., Chuang, W.-L., Stepanova, T., Hui, A.-J., Lim, Y.-S., Mehta, R., Janssen, H. L. A., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30107-8 · Cited by 554
Chan, H. L. Y., Fung, S., Seto, W. K., Chuang, W.-L., Chen, C.-Y., Kim, H. J., Hui, A. J., Janssen, H. L. A., Chowdhury, A., Tsang, T. Y. O., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30024-3 · Cited by 469
Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B
Heathcote, E. J., Marcellin, P., Buti, M., Gane, E., De Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.011 · Cited by 462
Lok, A. S., Zoulim, F., Locarnini, S., Bartholomeusz, A., Ghany, M. G., Pawlotsky, J.-M., Liaw, Y.-F., Mizokami, M., & Kuiken, C. (2007) · Hepatology · doi:10.1002/hep.21698 · Cited by 447
Metadata
- Authors
- Delaney, W. E., Ray, A. S., Yang, H., Qi, X., Xiong, S., Zhu, Y., & Miller, M. D.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2006-07
- Volume
- 50
- Issue
- 7
- Pages
- 2471-2477
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2134595040
- Cited by
- 259
- References
- 23
- FWCI
- 14.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus. https://app.cochat.ai/papers/10.1128/aac.00138-06
- The paper
- Delaney, W. E., Ray, A. S., Yang, H., Qi, X., Xiong, S., Zhu, Y., & Miller, M. D. (2006). Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00138-06
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.